Aug 2, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR All regulatory clearances received for the acquisition of Vifor Pharma AG Settlement of the offer is scheduled for 9 August 2022 Seasoned biopharma...
Jul 13, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Melbourne, Australia, and St. Gallen, Switzerland, 13 July 2022 – CSL Limited (ASX: CSL; USOTC:CSLLY) today announced an update regarding the Vifor...
May 12, 2022
St. Gallen, Switzerland, 12 May 2022 – CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to...
Apr 28, 2022Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients First launches in Europe...
Apr 26, 2022
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Dividend of CHF 2.00 approved All Board members re-elected...